Long-acting injectable HIV meds for adults 60 and older
Part of Infections clinical trials.
This study tests whether two long-acting injectable HIV medications (cabotegravir and rilpivirine) can keep the virus under control in people aged 60 and older. It aims to offer a convenient alternative to daily pills for older adults with HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years or older and living with HIV.
- You have been on a stable HIV medication plan without any changes due to treatment failure.
- Your viral load has been very low (under 50 copies per mL) for at least 6 months.
- You have no history of resistance to the drug classes NNRTI or integrase inhibitors.
- You are willing to receive injections of cabotegravir and rilpivirine every 2 months for 24 months.
- If you are female, you must not be pregnant, planning pregnancy, or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study follows people living with HIV who have undetectable viral loads to see how well a long-acting injectable medication (cabotegravir plus rilpivirine) works in real-world conditions. It may help understand if this injection-based treatment can reliably keep HIV controlled with fewer pills.
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
This study looks at switching people with HIV from daily or regular oral medicine to long-acting injections (cabotegravir plus rilpivirine). It may help those who are well-controlled on current therapy who prefer injections and can safely take this combination.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
This study looks back at medical records of people with HIV-1 who have received a long-acting injectable treatment called cabotegravir plus rilpivirine. It aims to see how well this treatment works for people with a specific HIV subtype (A6).
Hear when a new HIV-1 Infected Adults with Controlled Viremia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.